Studie zur Bewertung der Sicherheit und Wirksamkeit von Mirivadelgat bei PH-ILD (WINDWARD)
Eine multinationale, randomisierte, doppelblinde, placebokontrollierte Mehrfachdosisstudie der Phase 2 zur Bewertung der Sicherheit und Wirksamkeit von Mirivadelgat, einem Aldehyd-Dehydrogenase-2-Aktivator, bei Patienten mit pulmonaler Hypertonie im Zusammenhang mit interstitieller Lungenerkrankung (PH-ILD)
The goal of this clinical trial is to see if mirivadelgat will work in participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat. The main question it aims to answer is if mirivadelgat will improve pulmonary vascular resistance (PVR). Pulmonary vascular resistance is a way to measure blood flow in the lungs.
Researchers will compare mirivadelgat to a placebo (a look-alike capsule that contains no drug) to see if mirivadelgat works to improve the symptoms of PH-ILD. The symptoms of PH-ILD that are being looked at are exercise tolerance, heart function, and general well-being.
Participants will:
Take mirivadelgat or a placebo once a day for 12 weeks
Visit the clinic once every 4 weeks for checkups and tests
Receive phone calls every one or two weeks to check on how things are going
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The study is a phase 2, multinational, double-blind, 3-arm study to evaluate the safety and efficacy of mirivadelgat, an aldehyde dehydrogenase 2 activator, in adult subjects (aged 18 to 85 years) with PH-ILD. Participants must have a confirmed diagnosis of ILD as defined by the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and/or Latin American Thoracic Society (ALAT) guidelines (Raghu, 2018). The diagnosis is based on a HRCT either performed at screening or within 180 days prior to screening or a historical surgical biopsy (or other appropriate tissue sampling (e.g., cryobiopsy)) and an RHC performed at screening.
To be eligible for the study, a participant must be willing to undergo a Right Heart Catheterization (RHC) during screening and at the Week 12 Visit (at the end of study treatment). Participants on chronic treatment for underlying pulmonary diseases must be on a stable/optimized dose for ≥30 days prior to screening and have been receiving treatment for ≥90 days prior to screening.
The study will enroll approximately 126 participants, assuming a drop-out rate of 20%, to obtain 99 evaluable participants (33 evaluable subjects in each cohort).
Study visits will include a Screening Visit; Visit 2 (Study Day 1); Weeks 2, 3, 4, 6, 8,10, and 12 Visits (+/ 3 days); and a safety Follow-up Visit (+/ 3 days) after the Week 12 Visit. Visits on Weeks 2, 3, 6, and 10 will be conducted by phone calls.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Bassem Elmankabadi, MD
- Telefonnummer: +1 562-310-8718
- E-Mail: Bassem.elmankabadi@foreseepharma.com
Studieren Sie die Kontaktsicherung
- Name: Yisheng Lee, MD
- Telefonnummer: 408-823-4807
- E-Mail: yisheng.lee@foreseepharma.com
Studienorte
-
-
-
Banja Luka, Bosnien und Herzegowina, 78000
- Noch keine Rekrutierung
- University Clinical Centre of the Republic of Srpska
-
Sarajevo, Bosnien und Herzegowina, 71000
- Noch keine Rekrutierung
- Clinical Center of the University of Sarajevo
-
-
-
-
-
Kaohsiung City, Taiwan, 813
- Beendet
- Kaohsiung Veterans General Hospital
-
Taipei, Taiwan, 104
- Rekrutierung
- MacKay Memorial Hospital
-
Hauptermittler:
- Yih-Jer Wu, MD
-
Kontakt:
- Yu-Ping Huang
- Telefonnummer: 886-0975-835-863
- E-Mail: a6284@mmh.org.tw
-
-
Taiwan
-
Hualien City, Taiwan, Taiwan, 970
- Rekrutierung
- Hualien Tzu Chi Hospital
-
Hauptermittler:
- Wei-Hsin Liu, M.D.
-
Kontakt:
- Wei-Tung Lin
- Telefonnummer: 866-988431106
- E-Mail: tonton711223@gmail.com
-
Kaohsiung City, Taiwan, Taiwan
- Beendet
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Taichung, Taiwan, Taiwan, 407219
- Rekrutierung
- Taichung Veterans General Hospital
-
Hauptermittler:
- Pin-Kuei Fu, M.D.
-
Kontakt:
- Hui-Chih Yang
- Telefonnummer: 6523 866-04-23592525
- E-Mail: gina2066@gmail.com
-
Tainan, Taiwan, Taiwan, 704
- Beendet
- National Cheng Kung University Hospital
-
Taipei, Taiwan, Taiwan, 11217
- Rekrutierung
- Taipei Veterans General Hospital
-
Kontakt:
- Chun-Yi Lin
- Telefonnummer: 0955-636-508
- E-Mail: cylin23@vghtpe.gov.tw
-
Hauptermittler:
- Shih-Hsien Sung, M.D.
-
Kontakt:
- Coka Wang
- Telefonnummer: 866-0989-532-530
- E-Mail: Swwang3@vghtpe.gov.tw
-
Taipei, Taiwan, Taiwan, 100225
- Rekrutierung
- National Taiwan University Hospital
-
Hauptermittler:
- Ping-Hung Kuo, M.D.
-
Kontakt:
- Sui-Han Chen
- Telefonnummer: 265445 866-2 2312-3456
- E-Mail: suihanchen@hotmail.com
-
Taoyuan City, Taiwan, Taiwan
- Rekrutierung
- Chang Gung Memorial Hospital - Linkou Branch
-
Hauptermittler:
- Wan-Jing Ho, M.D.
-
Kontakt:
- Yi-Ping Chi
- Telefonnummer: 886-0978-055-798
- E-Mail: chiyiping1016@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
A clinical diagnosis of PH-ILD.
-
Participant voluntarily gives informed consent.
-
Male or female participants aged between 18 and 85 years at the time of signing informed consent.
-
Participants must agree to practice protocol-defined birth control during the study period, unless they meet criteria for not being of childbearing potential.
-
Male participants with female partners of childbearing potential must practice protocol- defined birth control for the duration of treatment and at least 96 hours after discontinuing the IP.
-
Female participants of childbearing of potential (including those <1-year post-menopausal) must practice protocol-defined birth control during the conduct of the study and for 30 days after the last dose of IP (males only during exposure to IP).
-
Female participants not of childbearing potential (as defined below) are eligible for enrolment without contraception requirements:
- Post-menopausal women (at least 12 months with no menses without an alternative medical cause); in women <45 years of age, a high follicle-stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy; OR
- Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; OR
- Have a congenital or acquired condition that prevents childbearing.
-
-
The participant has a confirmed diagnosis of any form of interstitial lung disease based on high-resolution computed tomography (HRCT) of the chest within 180 days prior to screening or at screening or a historical surgical biopsy (or other appropriate tissue sampling (e.g., cryobiopsy). The participant can have other findings (e.g., emphysema) if this is not the predominant feature on the scan.
-
Participants have undergone RHC during the screening period with the following documented parameters:
- Pulmonary vascular resistance (PVR) ≥4 Wood units and
- Pulmonary capillary wedge pressure (PCWP) of ≤12 mmHg [if PVR ≥4 Wood units to <6.25 Wood units] or PCWP ≤15 mmHg [if PVR ≥6.25 Wood units] Note: If a reliable PCWP cannot be obtained, left ventricular end-diastolic pressure (LVEDP), measured via left heart catheterization (LHC), will be acceptable, with the same numerical thresholds as the PCWP criterion: LVEDP of ≤12 mmHg [if PVR ≥4 to <6.25 Wood units], or LVEDP ≤15 mmHg
- A mean pulmonary arterial pressure (PAP) of >20 mmHg.
-
Participants must have a 6-minute walk distance ≥100 meters and ≤500 meters at the Screening Visit (Visit 1).
-
Participants agree to a repeat RHC, Chest CT, and MRI prior to study completion.
-
Participants on chronic treatment for underlying lung disease (i.e., nintedanib or pirfenidone or immunosuppressive agents etc.) must be on a stable/optimized dose for ≥30 days prior to screening and have been receiving treatment for ≥90 days.
-
Participants on supportive medications (e.g., inhalers for asthma) must be on stable doses for ≥30 days prior to screening.
-
In the Investigator's opinion, the participant must be able to consent for themselves and communicate with local staff using interpreters if necessary. Participants must agree to attend all study visits and be contactable through a cellular device or landline.
-
Participants must have clinical laboratory values within normal ranges or <1.5 times the upper limit of normal (ULN) as specified by the testing laboratory.
-
Participants must meet the following requirements for the pulmonary function test (PFT) at screening:
- Forced vital capacity (FVC) <90% of predicted
- Diffusion capacity of carbon monoxide (DLCO) <70% of predicted, or <70% of predicted corrected for hemoglobin (Hb), if correction is required. (Correction applies if Hb value is ≥25% and ≤90% of normal.) Note: DLCO must be determined locally at screening, using American Thoracic Society (ATS) standards. Hemoglobin correction should reference ATS normal values: Men = 14.6 g/dL, Women = 13.4 g/dL.
-
Negative serology test for hepatitis B surface antigen and hepatitis C antibody at Screening Visit.
Exclusion criteria:
Medical Conditions
-
Participant has another concomitant diagnosis of pulmonary hypertension not otherwise considered to be PH-ILD. This would include and is not limited to the concomitant presence of thromboembolic disease, untreated/inadequately treated obstructive sleep apnea, human immunodeficiency virus (HIV), methamphetamine or anorexigenic drug use, and other conditions of the WHO Group 1, 2, 4, and 5 classifications.
-
Participant has evidence of clinically significant left-sided heart disease within 6 months of screening as defined by:
- Left ventricular ejection fraction <40% as assessed by echocardiography.
- More than mild left-sided valvulopathy (e.g., worse than mild mitral stenosis or regurgitation and worse than mild aortic stenosis or regurgitation).
- LVEDP or PCWP >15 mmHg (or >12 mmHg if PVR ≥4 to 6.25 Wood units).
-
Participants must NOT have 3 or more of the following left ventricular disease/dysfunction risk factors at screening:
-
Body mass index (BMI) ≥30 kg/m2.
-
Uncontrolled diabetes, as evidenced by HbA1C >9.5%, or urine glycosuria >1.0 g/dl, or presence of diabetic ketoacidosis.
-
History of significant coronary disease within 6 months of screening as demonstrated by any of the following:
- History of myocardial infarction or acute coronary syndrome (unstable angina), or
- Percutaneous coronary intervention or percutaneous transluminal angioplasty, or previous coronary artery bypass graft, or
- Evidence of coronary artery disease (>50% stenosis in at least one major coronary artery) or abnormal nuclear stress test.
-
-
The participant is receiving ≥10 L/min of oxygen supplementation by any mode of delivery at rest.
-
The participant has received any PH-approved therapy, including soluble guanylate cyclase inhibitors, endothelin receptor antagonists, or parenteral or oral prostacyclin therapy (excluding vasoreactivity testing) within 60 days of randomization or 5 half-lives. Use of phosphodiesterase type 5 inhibitors and inhaled prostacyclin (e.g., inhaled treprostinil) on stable doses for ≥30 days prior to screening will be allowed irrespective of local approval (as per ESC/ERS 2022).
-
Use of any inhibitors and inducers of cytochrome P450 3A4 (CYP3A4) (e.g., boceprevir, cobicistat, danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, telithromycin, troleandomycin, voriconazole, clarithromycin, idelalisib, nefazodone, nelfinavir, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort). For a comprehensive list, please refer to the FDA's Examples of Drugs that Interact with CYP Enzymes and Transporter Systems (FDA 2025).
-
Recent exacerbation of underlying lung disease or active pulmonary/upper respiratory tract infection within 4 weeks of randomization.
-
Any current active malignancy (this does not include localized cancers such as basal or squamous cell carcinoma of the skin). Any history of malignancy that is likely to result in mortality or require significant medical or surgical intervention within the following year.
-
Chronic kidney disease Stage IV or greater (i.e., eGFR ˂30 mL/min/1.73m2) or evidence of acute kidney injury.
-
The participant has a history of congenital heart disease, irrespective of any prior treatment or surgical intervention
-
Use of tobacco, e-cigarette, nicotine, or marijuana products or a significant history of drug or alcohol abuse within 6 months of screening.
-
Acute pulmonary embolism within 90 days of screening.
-
Participation in pulmonary rehabilitation within 90 days of screening. However, participants who were on stable pulmonary rehabilitation for more than 90 days before screening may be considered for the study, provided they meet all other inclusion criteria.
-
Prior or concurrent use of any investigational drug/device/therapy or participation in any investigational study with therapeutic intent within 30 days or 5 half-lives, whichever is longer, before the first dose of the IP.
-
BMI ≥40 kg/m2.
-
Uncontrolled hypertension as evidenced by systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg during the screening period. Participants who fail screening due to high blood pressure can be re-screened once after their antihypertensive medications have been adjusted and their doses have been stable for at least 4 weeks.
-
Concomitant disease that confers a life expectancy of <6 months at screening.
-
The Investigator judges that the participant will be unable to fully participate in the study and complete it for any reason, including inability to comply with the study procedures and treatment of addiction or any other relevant medical or psychiatric conditions.
-
High likelihood of lung transplantation (in the opinion of the Investigator) within 4 months after randomization.
-
History of liver dysfunction, including participants with moderate (Child-Pugh B) or severe (Child-Pugh C) impairment or disordered coagulation.
-
Female participants who are pregnant or breastfeeding.
-
Worse than mild untreated sleep apnea (5-14.9 events/hour). Treated sleep apnea is permitted.
-
Participants with a prior diagnosis of connective tissue diseases, e.g., systemic sclerosis (scleroderma), systemic lupus erythematosus, Sjogren's disease, polymyositis/dermatomyositis/antisynthetase syndrome, or rheumatoid arthritis.
Other Exclusions
-
History of allergic or anaphylactic reaction to mirivadelgat or to any component of the excipient.
-
Previous exposure to mirivadelgat.
Diagnostic Assessments
-
The following laboratory parameters are excluded:
- Hemoglobin <10 g/dL (100 g/L).
- White blood cells (WBC) <3000/µL (<3000/mm3).
- Platelet count <70,000/µL (70,000/mm3).
- Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 or evidence of acute kidney injury.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: 150 mg mirivadelgat
150 mg mirivadelgat once daily |
Selective aldehyde dehydrogenase 2 (ALDH2) activator
Andere Namen:
|
|
Experimental: 300 mg mirivadelgat
300 mg mirivadelgat once daily |
Selective aldehyde dehydrogenase 2 (ALDH2) activator
Andere Namen:
|
|
Placebo-Komparator: placebo
placebo once daily |
placebo |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pulmonary Vascular Resistance (PVR)
Zeitfenster: 12 weeks
|
The mean change from baseline to Week 12 in PVR assessed by right heart catheterization (RHC) for mirivadelgat vs. placebo. |
12 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
6-minute walk distance
Zeitfenster: 12 weeks
|
The mean change from baseline to Week 12 in the 6-minute walk distance |
12 weeks
|
|
Time to clinical deterioration from baseline to Week 12 for any of the following ADJUDICATED clinical events
Zeitfenster: 12 weeks
|
|
12 weeks
|
|
Long-term prognostic risk factors
Zeitfenster: 12 weeks
|
The mean change from baseline to Week 12 of long-term prognostic risk factors of plasma/serum N-terminal pro-brain natriuretic peptide (NT-ProBNP), C-terminal procollagen I (PICP), N-terminal procollagen I (NICP or PINP), and N-terminal procollagen III (NIIICP or PIIINP). |
12 weeks
|
|
Patient-reported outcome measures (PROMS): (SF)-36v2
Zeitfenster: 12 weeks
|
The change from baseline to Week 12 in the Short Form (SF)-36v2 Health Survey with Scale 0 to 100 (mean is 50), 0 is worst, 100 is best |
12 weeks
|
|
Patient-reported outcome measures (PROMS): WIQ
Zeitfenster: 12 weeks
|
The change from baseline to Week 12 in the Walking Impairment Questionnaire (WIQ) with percentage scale ranging from 0% (worst) to 100% (best) |
12 weeks
|
|
Patient-reported outcome measures (PROMS): PAH-SYMPACT
Zeitfenster: 12 weeks
|
The change from baseline to Week 12 in the Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire (PAH-SYMPACT) with each point scored from 0 (best) to 4 (worst) |
12 weeks
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Inflammatory markers
Zeitfenster: 12 weeks
|
The mean change in concentration of inflammatory markers interleukin-6 (IL-6), high-sensitivity C-reactive protein (HS-CRP), and tumor necrosis factor- α (TNF-α) from baseline to Week 12. |
12 weeks
|
|
Change in Biomarkers
Zeitfenster: Week 12
|
The mean change in biomarkers related to fibrogenesis, inflammation, tissue destruction, and epithelial damage, including but not limited to PRO-C3, PRO-C6, C1M, C3M, C6M, C4Malph3, VICM, and CC16-HNE, from baseline to Week 12 |
Week 12
|
|
Cardiac MRI fibrosis score
Zeitfenster: 12 weeks
|
The mean change in cardiac MRI fibrosis score assessed by cardiac MRI gadolinium enhancement from baseline to Week 12 with a continuous variable that is not presented on a scale (only for subjects who have no contraindication to MRI procedure). |
12 weeks
|
|
Quantitative ILD features
Zeitfenster: 12 weeks
|
The change in Quantitative ILD features [i.e., Ground glass (QGC), Lung fibrosis (QLF), and Honeycombing (QHC)] assessed by HRCT scan from baseline to Week 12. |
12 weeks
|
|
Risk for intervention
Zeitfenster: 12 weeks
|
The Absolute Risk for intervention regarding specific events of death and stroke (CVA) (the absolute risk reduction between placebo and treatment of the composite event of death and stroke) |
12 weeks
|
|
Change of right ventricle/left ventricle (RV/LV) size
Zeitfenster: 12 weeks
|
The mean change in transthoracic echocardiography measurement of right ventricle/left ventricle (RV/LV) size, function, and strain from baseline to Week 12. |
12 weeks
|
|
Pulmonary function tests (PFTs) - FEV1
Zeitfenster: 12 weeks
|
The change in FEV1 from baseline to Week 12. |
12 weeks
|
|
Pulmonary function tests (PFTs) - FEV1 / FVC ratio and diffusion capacity of carbon monoxide (DLCO)
Zeitfenster: 12 weeks
|
The change in FEV1 / FVC and DLCO from baseline to Week 12. |
12 weeks
|
|
Pharmacokinetic (PK) parameters: T1/2
Zeitfenster: 12 weeks
|
T1/2 for mirivadelgat and its active metabolite AD-835. |
12 weeks
|
|
Pharmacokinetic (PK) parameters: AUC
Zeitfenster: 12 weeks
|
AUC for mirivadelgat and its active metabolite AD-835. |
12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Studienleiter: Bassem Elmankabadi, MD, Foresee Pharmaceuticals
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- FP-045C-23-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .